Psychedelic compounds show real promise for PTSD, but proving it requires solving unblinding, bias, and safety gaps in trial design.

Discover how ctDNA could transform early cancer detection and why the BRCA model offers important lessons for balancing innovation, risk, and meaningful patient outcomes.

See how CROs are helping shape the future of ctDNA research—translating emerging data, regulatory insights, and biomarker innovation into faster, smarter oncology development.

M&A transitions can either preserve momentum or create costly setbacks. Learn how protecting institutional knowledge helps sponsors reduce risk, maintain continuity, and accelerate development.

Global regulators are increasingly aligned, creating new opportunities for sponsors to pursue near-simultaneous submissions across major markets

Learn how you can navigate the complexity of rare disease development with flexible trial design, integrated regulatory strategy, and data-driven execution built for small populations and global programs.

How does specialized knowledge compound over time into foresight, stronger execution, and more confident decision-making across the drug development lifecycle?

PTSD trials expose one of the hardest problems in modern drug development, a reliance on clinician-administered and patient-reported scales to determine whether a therapy truly works.

The regulatory environment for cell and gene therapies (CGTs) is evolving rapidly, requiring sponsors to adopt a more strategic, integrated development approach.

Project Optimus represents a transformative shift in oncology, advocating for a more nuanced, evidence-based approach to dose selection, prioritizing patient safety alongside treatment effectiveness.

In response to insufficient traditional dose-escalation methods, regulatory initiatives like the FDA’s Project Optimus advocate for identifying optimal biological doses rather than relying solely on maximum tolerated doses (MTD).

From selecting appropriate targeting molecules to optimizing dosing strategies and managing off-target effects, radiopharmaceutical development demands a tailored and strategic clinical approach.

True team integration transcends basic collaboration, requiring the dismantling of barriers between sponsors and vendors, eliminating departmental silos, and cultivating mutual accountability.

Conducting multi-regional clinical trials (MRCTs) is essential for accelerating oncology drug development and ensuring broader patient access. However, differences across regions can impact findings.

Through proactive timeline management and strategic oversight, organizations can achieve their regulatory goals with confidence.

Clinical trials are inherently complex, and even well-structured studies may struggle to achieve statistical significance due to challenges in study design, patient selection, and data variability.

Learn about adaptive design (AD) trials that reduce clinical trial time and cost while enhancing patient safety by minimizing exposure to unsafe or ineffective treatments.

Discover why the differences between individuals and diseases are crucial when crafting a clinical development program.

Get a recap of what industry experts had to say about single-arm oncology registrational studies, success stories, and valuable lessons learned.

Explore some of the key takeaways from the Tufts CSDD Roundtable on quantifying the value proposition of decentralized clinical trial deployments.

Learn more about what a Functional Service Provider (FSP) is, and review key points to consider when deciding if a functional service approach could better serve a clinical team and its study.

Discover how this terminology change will require the investment of time and resources to deliver its full potential.

Explore how effectively managing the publishing of documents required for a marketing application submission can help accelerate the time it takes to bring your product to market.  

In this blog, explore both autologous and allogeneic approaches, the solutions needed to optimize the development processes for commercial viability, and the future landscape of cell therapies in the rare disease space.

Read this webinar presentation as panelists share lessons learned and recommendations for designing protocols that enable flexibility in your virtual trials’ conduct.

Today, the shift and the changes in how we work has affected how clinical trial monitoring is conducted and performed. Explore how re-tooling the clinical monitoring in clinical trials has become imperative.

The recent FDA guidance entitled "Human Gene Therapy for Neurodegenerative Diseases" (ND) provides recommendations for Sponsors who are developing human gene therapy (GT) products for neurodegenerative diseases, which affect adult and pediatric patients. It focuses on considerations for product development, preclinical testing, clinical trial design and marketing approval pathways. This article outlines several areas to consider when preparing for regulatory agency interactions.

See how strategic EU dossier adaptation and Swiss-specific regulatory expertise enabled a successful SwissMedic submission and accelerated market access for an oncology therapy.

Discover how an integrated NDA strategy aligned data, vendors, and regulatory execution to achieve an on-time submission and approval without major FDA queries.

Facing EU MAA complexity? Learn how one oncology sponsor met a fixed EMA deadline through global regulatory coordination, rapid dossier adaptation, and real-time submission execution.

Managing a complex sNDA under pressure? See how one sponsor achieved an early FDA submission through coordinated publishing, regulatory strategy, and flawless execution.

Global approvals for a first-in-class gene therapy don’t happen by chance. See how adaptive oversight and inspection readiness kept a complex rare disease program moving forward.

What is a Simon 2-stage design, and how was it used to enable each tumor-specific cohort in a Phase 2, multi-cohort oncology trial to be independently assessed for objective response rates?

Learn how early FDA alignment can help your neurology program move forward with greater clarity, confidence, and regulatory readiness.

No two new drug applications (NDAs) or marketing authorization applications (MAAs) are the same. Learn the key strategies that can be implemented to propel even the most complex submissions to successful regulatory conclusions.